Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Frost & Sullivan Recognizes Iris BioTechnologies for Technology Innovation in the Pharmacogenomics Arena - Based on its recent analysis of the pharmacogenomics market, Frost & Sullivan presents Iris BioTechnologies Inc. (Iris) with the 2008 North American Frost & Sullivan Award for Technology Innovation
Frost & Sullivan Recognizes Iris BioTechnologies for Technology Innovation in the Pharmacogenomics Arena

 

PRZOOM - /newswire/ - Palo Alto, CA, United States, 2008/07/07 - Based on its recent analysis of the pharmacogenomics market, Frost & Sullivan presents Iris BioTechnologies Inc. (Iris) with the 2008 North American Frost & Sullivan Award for Technology Innovation.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The Award recognizes the firm’s remarkable efforts toward the development of a patented, integrated technology platform, the Nano-Biochip™ gene expression diagnostic system and an artificial intelligence bioinformatics platform, called BioWindows™.

The Nano-BioChip™ and informatics system together is designed to assist physicians in quickly prescribing the most effective, customized treatment protocol for patients based on their genetic imprints and other aspects central to a disease’s incidence, such as lifestyle and environmental factors. For patients, this technology would be pivotal in yielding a personalized treatment regimen, with the greatest possibility of success.

“Iris has the capability to employ its Nano-BioChip™ technology and BioWindows™ platform to cater to a wide spectrum of diseases such as cancer, diabetes, heart disease, neurological disorders and other gene-related metabolic problems,” says Frost & Sullivan Research Analyst Vanitha S. V. “However, the firm’s primary focus is to develop an effective and reliable Nano-BioChip™ for the prognosis of breast cancer.”

Devised as BreastCancerChip™, Iris’ Nano-BioChip™ gene expression diagnostic technology for breast cancer, is designed to capture crucial molecular information concerning the activity of more than one hundred genes implicated in breast cancer, from a breast biopsy sample. The breast biopsy sample obtained can be processed to obtain tissue RNA, which can be compared to 100 predefined gene markers, associated with breast cancer. An optical pattern is created based on the number of target gene markers on the Nano-BioChip™, to which the sample tissue RNA is bound.

The optical pattern thus obtained can be analyzed using the BioWindows™ bioinformatics platform. This proprietary artificial intelligence system is a centralized, expandable database, which gathers patients’ personal information, medical history, including their environmental, lifestyle and hereditary dispositions via a comprehensive online survey. The optical pattern is analyzed by comparing the pattern to historical clinical reference information contained within Iris’ database.

“While the Nano-BioChip™ captures the patient’s genomic profile, the BioWindows™ reference database and computer program serves as a complementary platform to analyze the specimen gene profile and deliver a rapid, secure, confidential and detailed diagnostic report to the patient’s designated physician, which assists them to identify a unique, optimal medical treatment solution for each patient,” remarks Vanitha. “Iris has thus demonstrated tremendous foresight toward the discovery and development of a breakthrough proprietary technology platform that could be pivotal in engendering the most appropriate customized treatment option.”

Iris launched its BioWindows™ platform globally on Mother’s Day, May 11, 2008 and plans to launch its first product, the BreastCancerChip™, later this year. Some of Iris’s other products in development based on the same technology platform include other chips such as the NeuroChip™, CardioChip™, and MetabolicChip™ for human use, and specialized and proprietary chips for veterinary, agricultural, and environmental applications.

In summary, Iris’s technology is a near-term opportunity that could significantly transform the way in which personalized medication is currently being prescribed. In recognition of Iris’s remarkable efforts in engendering a radical technology in the field of disease theranostics, Frost & Sullivan is honored to present Iris BioTechnologies with the 2008 Award for Technology Innovation.

Each year, Frost & Sullivan presents this Award to the company that has carried out new research, which has resulted in innovation(s) that have or are expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The Award recognizes the quality and depth of a company’s research and development program as well as the vision and risk-taking that enabled it to undertake such an endeavor.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Iris BioTechnologies Inc.
Iris BioTechnologies (irisbiotech.com), located in Santa Clara, CA, is a theranostics company, dedicated to creating a novel approach to monitor gene expression levels and mutations in order to identify the ideal treatment solution for patients. By categorizing individuals according to their genomic and personal profiles, Iris BioTechnologies accurately determines the optimal medical solution for each patient through a proprietary informatics program, BioWindows. Iris’s ever expanding database, in addition to their developments of the Comprehensive Cancer Chip, NeuroChip, CardioChip, and MetabolicChip adds to their extensive product pipeline. The company’s first biochip, the BreastCancerChip, is expected to be available in the second half of 2008.

The Investor Relations Group
212-825-3210
Investor Relations:
Conrad Mir or Christine Berni
E: conrad[.]investorrelationsgroup.com.
E: christine[.]investorrelationsgroup.com.

Media Relations:
Lynn Granito
E: lynn[.]investorrelationsgroup.com.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Recognizes Iris BioTechnologies for Technology Innovation in the Pharmacogenomics Arena

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Stacie Kopecki 
210.247.2450 stacie.kopecki[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  NAKIVO, Inc.







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today